Evoke Pharma's Gimoti On Way To US FDA On 'Mixed' Data
Executive Summary
Evoke Pharma's share price fluctuated wildly after it announced new data for its gastroparesis therapy that were not quite as positive as they first appeared. A US filing is scheduled.
You may also be interested in...
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
The latest drug development news and highlights from our US FDA Performance Tracker.
10 Approvals To Look Out For In Q3 2023
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.